Q2 EPS Forecast for Oruka Therapeutics Increased by Analyst

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Equities research analysts at HC Wainwright lifted their Q2 2026 earnings per share (EPS) estimates for shares of Oruka Therapeutics in a research report issued on Monday, May 18th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.56) per share for the quarter, up from their prior estimate of ($0.59). HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($2.10) per share. HC Wainwright also issued estimates for Oruka Therapeutics’ Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.09) EPS, Q1 2027 earnings at ($0.55) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.68) EPS, Q4 2027 earnings at ($0.74) EPS and FY2027 earnings at ($2.56) EPS.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04.

Several other equities research analysts also recently weighed in on ORKA. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, April 21st. UBS Group raised their price target on Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Guggenheim set a $200.00 price target on Oruka Therapeutics and gave the stock a “buy” rating in a report on Monday, April 27th. Stifel Nicolaus raised their price target on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Finally, Barclays raised their price target on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $120.80.

Oruka Therapeutics Price Performance

Shares of ORKA stock opened at $57.50 on Wednesday. Oruka Therapeutics has a 1-year low of $10.16 and a 1-year high of $91.00. The stock’s 50-day moving average is $56.16 and its 200 day moving average is $39.85. The company has a market cap of $3.47 billion, a P/E ratio of -29.64 and a beta of -0.20.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Royal Bank of Canada raised its stake in shares of Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the last quarter. Kennedy Capital Management LLC raised its stake in shares of Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after purchasing an additional 420 shares during the last quarter. AlphaCentric Advisors LLC raised its stake in shares of Oruka Therapeutics by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after purchasing an additional 626 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Oruka Therapeutics by 35.0% in the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after purchasing an additional 788 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Oruka Therapeutics by 62.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock worth $71,000 after purchasing an additional 904 shares during the last quarter. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $61.85, for a total value of $432,950.00. Following the completion of the sale, the insider owned 33,377 shares of the company’s stock, valued at approximately $2,064,367.45. This trade represents a 17.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the sale, the chief executive officer directly owned 927,309 shares of the company’s stock, valued at approximately $38,297,861.70. This represents a 0.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 34,055 shares of company stock valued at $1,903,935. 23.49% of the stock is currently owned by corporate insiders.

Key Stories Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple earnings estimates for Oruka Therapeutics, including FY2026, FY2027, and several quarterly forecasts, while reiterating a Buy rating and $120 price target. The revisions suggest the firm sees a somewhat improved earnings outlook ahead. Oruka Therapeutics analyst estimate update
• Positive Sentiment: Broader Wall Street sentiment remains constructive, with several firms recently lifting targets and the stock still carrying a consensus Moderate Buy rating and a price target above the current trading range. Oruka Therapeutics analyst coverage overview
• Neutral Sentiment: CEO/C-suite selling was reported on a pre-arranged 10b5-1 plan, with SVP Arjun Agarwal selling 10,290 shares for about $607,830. Because the trade was preplanned, it is less likely to signal a fundamental change, but insider selling can still weigh on sentiment. Oruka Therapeutics insider sale article

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.